| Filed On | Filing |
|---|---|
| 23 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
PRINCETON, N.J., September 23, 2026 -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has regai... |
| 16 Sep 2026 |
Form 4: Chan Phillip P., Director
Bought 3,774 shares ($22.6K) |
| 16 Sep 2026 |
Form 4: Capponi Vincent, President and COO
Bought 2,073 shares ($12.5K) |
| 16 Sep 2026 |
Form 4: Sobel Alan D., Director
Bought 2,500 shares ($15.3K) |
| 09 Sep 2026 |
Form 4: Chan Phillip P., Director
Bought 200,000 shares ($70K) |
| 08 Sep 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
CytoSorbents Corporation, a corporation organized and existing by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify: |
| 14 Aug 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 07 Aug 2026 | 8-K: Regulation FD Disclosure |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 06 Jul 2026 | 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule |
| 25 Jun 2026 | ARS |
| 25 Jun 2026 | DEFA14A |
| 25 Jun 2026 |
Proxy statement: annual meeting on August 13, 2026
CEO pay $808K, down 10% · say-on-pay vote |
| 25 Jun 2026 | 8-K: Regulation FD Disclosure |
| 16 Jun 2026 |
Form 4: Mariani Peter J, Chief Financial Officer
Bought 100,000 shares ($44K) |
| 15 Jun 2026 |
Form 4: Chan Phillip P., Director
Bought 251,136 shares ($100K) · Bought 10,333 shares ($4.44K) |
| 11 Jun 2026 | PRE 14A |
| 13 May 2026 | 10-Q |
| 13 May 2026 | 8-K: Results of Operations and Financial Condition |
Loading...
